Personalized Neoantigen Peptide Immunotherapy in Glioblastoma: From Pre-screening to Clinical Phase 1

• Pre-screening in glioblastoma – Identifying patients with sufficient tumor material and actionable neoantigen profiles for a personalized, targeted peptide-based immunotherapy
• Mechanistic basis and immune readouts – A targeted peptide-based approach designed to prime neoantigen-specific T-cell responses, with immune monitoring assays to capture activation, breadth, and durability
• Pathways to scalability – Identifying key drivers such as prediction accuracy, manufacturing performance, and workflow coordination that will enable future scaling of personalized peptide-based programs

Speakers:

Wolfgang Fischl

Chief Executive Officer

YGION Biomedical